Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Lexicon Pharmaceuticals, Inc. - Common Stock (NQ: LXRX )

0.3517 -0.0030 (-0.85%)
Streaming Delayed Price Updated: 3:38 PM EDT, Mar 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5,208,516
Open 0.3498
Bid (Size) 0.3516 (8)
Ask (Size) 0.3517 (7)
Prev. Close 0.3547
Today's Range 0.3300 - 0.3588
52wk Range 0.2836 - 2.829
Shares Outstanding 144,474,452
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
What Analysts Are Saying About Lexicon Pharmaceuticals Stock
Via Benzinga
Here are the top movers in Monday's session.
Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements. 
Via Chartmill

Performance

YTD
-54.74%
-54.74%
1 Month
-53.16%
-53.16%
3 Month
-52.22%
-52.22%
6 Month
-78.94%
-78.94%
1 Year
-87.48%
-87.48%

More News

Read More
Let's take a look at the stocks that are in motion in today's session.
Via Chartmill
Which stocks are gapping on Monday?
Via Chartmill
Lexicon Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
Via Benzinga
Analyst Expectations For Lexicon Pharmaceuticals's Future
Via Benzinga
Demystifying Lexicon Pharmaceuticals: Insights From 10 Analyst Reviews
Via Benzinga
Earnings Scheduled For March 6, 2025
Via Benzinga
Earnings Scheduled For November 12, 2024
Via Benzinga
Preview: Lexicon Pharmaceuticals's Earnings
Via Benzinga
The Analyst Landscape: 11 Takes On Lexicon Pharmaceuticals
Via Benzinga
Lexicon Pharmaceuticals (LXRX) Stock Is Down: What's Going On?
Via Benzinga
Monday's pre-market session: top gainers and losers
Via Chartmill
Published Data in The Lancet Diabetes & Endocrinology Highlights Unique Efficacy Benefits of Sotagliflozin to Reduce Major Adverse Cardiovascular Events (MACE)
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
9 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Lexicon Announces Virtual Webcast on LX9211 for Diabetic Peripheral Neuropathic Pain
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Lexicon Appoints Scott Coiante as Chief Financial Officer
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Lexicon Announces Receipt of Complete Response Letter for Zynquista™ (sotagliflozin)
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
2 Generic Drug Stocks Ready to Surge in 2025
Via MarketBeat
Topics Government Intellectual Property
Exposures Intellectual Property Political Product Safety
Lexicon Announces Completion of Enrollment in Phase 2B PROGRESS Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Lexicon Pharmaceuticals to Participate in December Investor Conferences
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Lexicon to Reposition as Clinical Development-Focused Company Following Regulatory Update From FDA
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Lexicon Appoints Ivan H. Cheung to Board of Directors
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
What You Missed On Wall Street This Past Friday
Via Talk Markets
Crude Oil Moves Higher; Apple Shares Slide After Q4 Results
Via Benzinga
Exposures Fossil Fuels
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.